Prevalence and characteristics of patients with HR+/HER2- early breast cancer who are eligible for adjuvant CDK4/6 inhibitor: a real-world cohort from China
@article{TBCR121505,
author = {Hao Xu and Yu Wang and Zhaojun Zhang and Li Jiang and Mingliang Jin and Jinhua Ding},
title = {Prevalence and characteristics of patients with HR+/HER2- early breast cancer who are eligible for adjuvant CDK4/6 inhibitor: a real-world cohort from China},
journal = {Translational Breast Cancer Research},
volume = {0},
number = {0},
year = {2026},
keywords = {},
abstract = {},
issn = {2218-6778}, url = {https://tbcr.amegroups.org/article/view/121505}
}